A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the Nati
about
Management of relapsed ovarian cancer: a reviewTrial watch - inhibiting PARP enzymes for anticancer therapyClinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancerNonsmall cell lung cancer therapy: insight into multitargeted small-molecule growth factor receptor inhibitorsIdentification of target genes of cediranib in alveolar soft part sarcoma using a gene microarray.Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study.Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering CommitteeA randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer.Angiogenesis in acute myeloid leukemia and opportunities for novel therapies.Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer.New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyondNew molecular targeted therapies for advanced non-small-cell lung cancer.Cediranib inhibits both the intraosseous growth of PDGF D-positive prostate cancer cells and the associated bone reactionAdding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancerAcute vascular response to cediranib treatment in human non-small-cell lung cancer xenografts with different tumour stromal architecture.Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancerTargeted therapies in non-small cell lung carcinoma: what have we achieved so far?A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503).Novel VEGF signalling inhibitors: how helpful are biomarkers in their early development?Tyrosine kinase inhibitors to treat liver cancer.New oral multitargeted antiangiogenics in non-small-cell lung cancer treatment.Cediranib: a VEGF receptor tyrosine kinase inhibitor.An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents.Pharmacokinetic Aspects of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors.Targeting Neovasculature with Multitargeted Antiangiogenesis Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer.Clinical Pharmacokinetics and Pharmacodynamics of Cediranib.Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study.Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24.Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies.Population exposure-safety analysis of cediranib for Phase I and II studies in patients with cancer.Population pharmacokinetic and exposure simulation analysis for cediranib (AZD2171) in pooled Phase I/II studies in patients with cancer.
P2860
Q26741755-CAD84A1E-E04E-4676-996D-78CD0FB2591EQ26745673-FA722A76-277A-4C9B-A1E3-1C2BC2D5DEBCQ27024235-15360C5F-5DA7-4797-A545-AA9F36652FD2Q27693185-3F1FEAEF-1765-4E40-800A-4EBF87F00095Q33598883-61CC3D08-22DD-4FF2-913F-3D1DAFB9ABEAQ33918044-0A84E4B6-AF64-4611-9AF7-DEA2E5D30967Q34056295-560B1550-E0F4-44A3-8616-081B58DD4D50Q34322552-39D82828-5026-4810-9380-4D153FBCE868Q34854658-D2C00B0A-76B7-4D42-87A0-195DCFBCE9A6Q35196950-2F4485AC-9AC0-4F43-8CE8-4E82B2F7D908Q35584074-AA3CFC78-E9E2-4657-890A-9F0807E1916BQ35660763-760FBAF2-CEFE-4874-87CF-94283A3E8A2CQ35667806-DFD7934D-7DA9-426A-89E5-0EFAAA35BD9BQ36013452-E4EF0948-1DAB-4418-8160-515118D71385Q36161541-8D4D8A30-C0E2-464E-A152-39859E5CE70BQ36270034-650CB924-D030-494E-86D4-915DC0D22C0AQ36337646-4005CE42-2624-4C35-A11E-DE0F5C9DB2A1Q36671812-1DE8555C-A130-41C2-8D84-CFA7EC5812C4Q36999705-7070E0BA-075B-4BDF-BF0B-0A8AB977F24EQ37111141-D071E0AA-575A-494A-A49D-97A327160172Q37624735-A2234946-4D35-4315-B594-B6D051339F17Q37686529-6E2AB1A6-1C0B-4D8D-8D71-CD7463FDA26DQ38014533-D3401F2C-4DE7-45CC-9318-DE98A675219BQ38029363-17D37DE3-4F2C-4FCD-81A2-DA967FF7E636Q38077494-77BF8E0A-6342-4700-995C-0BC4FA813615Q38552109-FC754290-3869-4C0C-9D21-3770F67957E6Q38964908-4FF5F745-2F5F-48F9-92E3-92C4152C5F33Q39036230-CA14C7A8-B3CB-4882-9E7D-99A220F64DB0Q39090350-E527CAFF-C7AB-4B81-AF7D-768492F8BD5DQ43081790-7E5B75B1-910F-456D-9447-A3AC23DB1FF6Q43515124-E4A942F1-6595-4D47-A2AF-98ADC07BEBE0Q48352556-7F0ED03C-490D-4C57-AB75-318E6B150625Q50885562-89E7882A-B851-4DC0-AF60-27EDAFC6EB5E
P2860
A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the Nati
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
A phase I and pharmacokinetic ...... ng cancer: a study of the Nati
@nl
type
label
A phase I and pharmacokinetic ...... ng cancer: a study of the Nati
@nl
prefLabel
A phase I and pharmacokinetic ...... ng cancer: a study of the Nati
@nl
P2093
P3181
P1476
A phase I and pharmacokinetic ...... f Canada Clinical Trials Group
@en
P2093
Frances A Shepherd
Glenwood Goss
Isabelle Gauthier
Jean Powers
Lesley Seymour
Ronald Feld
Scott Laurie
P3181
P356
10.1016/J.EJCA.2008.10.022
P407
P577
2009-03-01T00:00:00Z